Meta-analysis shows that XRCC1 Arg399Gln polymorphism may be a biomarker of glioma susceptibility

DNA damage is an important mechanism of glioma. X-ray cross-complementing group 1 (XRCC1) is a DNA repair gene that participates in the base excision repair pathway. To date, many studies have been performed to investigate the association between the XRCC1 polymorphisms and risk of cancers such as breast cancer, and gastroesophageal cancer, but the number of studies that focused on glioma is relatively small.

Evidence regarding the role of the single nucleotide polymorphisms in XRCC1 as genetic markers for glioma risk is inconsistent. Prof. Xinquan Gu and team from China-Japan Union Hospital of Jilin University, China performed a meta-analysis to identify statistical evidence for an association between the XRCC1 Arg399Gln, Arg194Trp, Arg280His polymorphisms and glioma risk by accumulating all published data. Meta-analysis results verified that the XRCC1 Arg399Gln polymorphism may be a biomarker of glioma susceptibility, especially in Asian populations. The Arg194Trp and Arg280His polymorphisms were found not to be associated with overall glioma risk. These findings, published in the Neural Regeneration Research (Vol. 8, No. 26, 2013), provide the necessary scientific basis for the glioma pathogenesis and glioma risk population screening.

Article: " Correlation between X-ray cross-complementing group 1 polymorphisms and the onset risk of glioma: a meta-analysis " by Xinquan Gu1, Hongyan Sun2, Liping Chang3, Ran Sun2, Hongfeng Yang4, Xuewen Zhang2, Xianling Cong2, 4 (1 Department of Urinary Surgery, China-Japan Union Hospital of Jilin University, Changchun 130033, Jilin Province, China; 2 Tissue Bank, China-Japan Union Hospital of Jilin University, Changchun 130033, Jilin Province, China; 3 Department of Cardiopathy, the Affiliated Hospital of Changchun University of Chinese Medicine, Changchun 130021, Jilin Province, China; 4 Department of Dermatology, China-Japan Union Hospital of Jilin University, Changchun 130033, Jilin Province, China)

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
AI models redefine TIL scoring in breast cancer but face challenges in real-world validation